Precigen, Inc. (NASDAQ:PGEN – Get Free Report) COO Rutul Shah sold 32,739 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. HC Wainwright boosted their price objective on Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research note on Friday, July 17th. Finally, Zacks Research raised shares of Precigen from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Precigen Company Profile(Get Free Report)Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines.